Background: Considering the high prevalence of female genital tract neoplasms, non-specific nature of the initial symptoms, higher possibility of metastasis by the time of diagnosis, importance of differentiating metastatic Mullerian tumors or metastatic breast cancer in the female genital tract, especially in the ovary, and lack of diagnostic markers with high sensitivity and specificity, the purpose of the current study was to evaluate the utility of Paired box protein8 (PAX8) expression in Mullerian and non-Mullerian neoplasms.
INTRODUCTION
Neoplasms of the female genital tract are considered as the third most common malignancy in women, with 
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Many immunohistochemical (IHC) markers are identified to determine the primary origin of the tumors, but most of them have relatively low sensitivity and specificity. Regarding the carcinomas of Mullerian origin, few specific IHC markers have been identified. Markers such as CA-125, ER, PR and WT-1 are often used in combination with other IHC markers to determine the possible Mullerian origin and the primary type of the tumors, [3] [4] [5] but they have limited value in this field because of low sensitivity and specificity.
Recent evidences support the utility of PAX8 factor in this regard, especially in determining Mullerian tumors. [6] [7] [8] Differentiation of ovarian metastatic tumors (especially with breast origin) from primary ovarian tumors can also be performed based on this IHC staining.
PAX8 is a member of the paired-box family of genes. It is expressed during organogenesis of the thyroid gland, Mullerian tract and kidney. The expression of PAX8 has been reported in renal, thyroid and ovarian neoplasms. [9, 10] Recent studies reported that PAX8 was considered as a surrogate marker for carcinoma of Mullerian origin. [11, 12] Considering the high prevalence of female genital tract neoplasms, non-specific nature of the initial symptoms, higher possibility of metastasis by the time of diagnosis and lack of diagnostic markers with high sensitivity and specificity, the purpose of the current study was to evaluate the utility of IHC PAX8 expression in Mullerian and non-Mullerian neoplasms.
MATERIALS AND METHODS
In this descriptive-analytic, cross-sectional study, paraffin-embedded tissues of 37 patients with definitive pathologic diagnosis of epithelial tumors of ovary, uterus and endocervical adenocarcinomas (Mullerian tumors) and 37 tissue sections from patients with definite diagnosis of non-Mullerian tumors (except for renal and thyroid) were retrieved from the pathology archives of Alzahra Hospital in Isfahan-Iran, from March 2008 to March 2010. All sections were selected by the simple sampling method.
The Medical Ethics Committee of the Isfahan University of Medical Sciences approved the study protocol (research project number; 390098). PAX8 IHC staining was performed for all selected blocks. IHC-stained slides were prepared for all specimens. The slides were evaluated by a pathologist using light microscopy. Immunopositivity for PAX8 was defined as the presence of nuclear staining in at least 10% of the tumor cell nuclei.
PAX8 immunohistochemistry staining method PAX8 IHC staining was done manually according to the proposed manufacturer protocol (abcam-Ab53490-UK) with the mouse polyclonal antibody.
In brief, 4-µm-thick paraffin-embedded sections were made and processed on the poly-L-lysine-coated slides. These slides were sunk in xylene and then in alcohol and finally in Tris-EDTA buffer with a pH of nearly 9 (at a temperature of 95°C and for 20 min) for deparafinazation and antigen retrieval. The next steps for staining were as follows: 
Statistical analysis
The data obtained were analysed using SPSS version 17 for windows software.
RESULTS
In this study, 37 Mullerian tumors, including 18 ovarian epithelial tumors (11 papillary serous carcinoma, three mucinous carcinoma, two endometrioid carcinoma, two clear-cell carcinoma), 15 endometrioid carcinoma of uterine corpus, one malignant mixed Mullerian tumor of uterine corpus, one papillary serous carcinoma of uterine and two endocervical adenocarcinoma and 37 nonMullerian tumors, including 14 breast carcinoma, seven colon, five gastroesophagial, five lung, three pancreas and three bladder carcinomas were retrieved from the pathology archives of the Alzahra Hospital.
Expression of PAX8, by IHC, in Mullerian and non-Mullerian tumors is presented in Table 1 and Figures 1-3 .
In total, in 29/37 tumors from the Mullerian tumors and in one of 37 tumors from the non-Mullerian tumors, the expression of PAX8 was positive. The sensitivity and specificity of PAX8 by IHC for differentiation of Mullerian from non-Mullerian tumors was 78.4% and 97.3%, respectively. 
DISCUSSION
In this study, the expression of PAX8 was determined in Mullerian and non-Mullerian tumors. Our findings indicated that PAX8 could be used as a useful IHC marker for the diagnosis Mullerian tumors with acceptable sensitivity and specificity. They concluded that it could be a useful marker in a histopathology laboratory setting for diagnosing the primary type of female genital tract tumors. [13] Ozcan and colleagues in a comprehensive IHC study have studied the expression of PAX8 in non-neoplastic tissues, primary tumors and metastatic tumors. According to their findings, 238/267 (89%) Mulleriantype neoplasms were positive for PAX8, and they concluded that PAX8 is a sensitive and specific marker for both primary and metastatic renal, Mullerian and thyroid tumors. [14] In this study, we investigated the IHC expression of PAX8 in determining the type and origin of the primary tumors. The utility of IHC in this field has been mentioned in previous studies.
[ 15] Recently, PAX8 expression in the Mullerian system has received considerable interest in the clinical and research fields. Many studies have reported positive expression of PAX8 in fallopian tube secretory cells,
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in distinguishing serous ovarian carcinoma from breast carcinoma and many ovarian/pelvic serous tumors. [11, 12, 16] Some other studies have reported its expression in non-serous ovarian tumors, the endometrium and also the cervix. [17] In this study, PAX8 was positive in the mentioned tumors and was negative in mucinous ovarian carcinomas and endocervical adenocarcinoma. In accordance to our study, Laury et al. have reported relatively low expression (40%) of PAX8 in primary mucinous ovarian carcinomas. [17] Lower expression of PAX8 in endocervical adenocarcinoma has been reported in other studies also. Tong and colleagues have reported similar results regarding mucinous ovarian carcinomas and endocervical adenocarcinoma. [8] However, the absence of PAX8 does not mean that the tumor is not ovarian or Mullerian in origin. The causes of such findings need further investigations.
In accordance with the study of Tong et al., in all types of the studied uterine carcinomas, PAX8 expression were positive, which may be related to the diffuse positive PAX8 staining in the normal endometrium.
Overall, these findings confirm the suggestions of previous studies regarding the sensitivity of this marker. The results of this study were similar to those of Tong et al. and Bowen et al. [8, 11] In this study, we determined the specificity of PAX8 by investigating its expression in non-Mullerian tumors. It was positive only in one case with bladder cancer. Our results showed that PAX8 was negative in 97.3% of non-Mullerian tumors (except for thyroid and renal carcinomas), which indicates its higher specificity in this regard. Our results were consistent with the reports of Wiseman et al. and Nonaka et al. [7, 11] It seems that a better conclusion would be achieved if we had studied a wider variety of non-Mullerian tumors.
In summary, PAX8 could be used as a useful IHC marker for diagnosing Mullerian tumors (except for mucinous adenocarcinoma of the ovary and adenocarcinoma of the cervix). It has moderate to high sensitivity, but a high specificity, for diagnosing carcinomas of Mullerian origin.
